Physician profile
Eric J Bartky
NPI 1023233426
$50,622.12
in general payments reported to CMS, 2019-2025
32 companies · $1,639 in 2025
The $1,639 reported for 2025 was more than what 92% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,428 · 2020: $261 · 2021: $18K · 2022: $22K · 2023: $1,267 · 2024: $1,481 · 2025: $1,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,387.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $39,386.05 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $5,081.41 | 2019-2024 | Jornay Pm |
| Abbvie INC. | $972.46 | 2022-2025 | Vraylar |
| Neos Therapeutics, LP | $710.43 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt, Exxua |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $687.57 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $672.32 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $448.55 | 2019-2025 | Rexulti |
| Tris Pharma INC | $417.64 | 2019-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $404.72 | 2019-2025 | Invega Sustenna, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $399.01 | 2019-2025 | Trintellix |
| Corium, LLC | $243.71 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $153.37 | 2019-2022 | |
| Axsome Therapeutics, INC. | $139.39 | 2023-2025 | Auvelity |
| Jazz Pharmaceuticals INC. | $132.26 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $92.84 | 2022-2025 | Ingrezza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhodes Pharmaceuticals L.P. | $79.90 | 2019 | |
| Validus Pharmaceuticals LLC | $65.02 | 2019-2020 | |
| Alkermes, INC. | $63.87 | 2021-2025 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $63.39 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $54.99 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $47.04 | 2025 | Uzedy, Austedo Xr |
| Neuronetics, INC. | $42.05 | 2019 | |
| Shire North American Group INC | $39.35 | 2019 | |
| Alfasigma USA, INC. | $37.36 | 2020-2021 | |
| Tempus Ai, INC | $31.87 | 2024 | |
| Avion Pharmaceuticals | $28.98 | 2023 | Methylphenidate Hydrochloride, Dhivy |
| Owp Pharmaceuticals, INC. | $27.56 | 2021-2024 | Subvenite |
| Vertical Pharmaceuticals, LLC | $26.71 | 2019-2020 | |
| Adlon Therapeutics L.P. | $26.25 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.53 | 2024 | |
| Glaxosmithkline, LLC. | $15.62 | 2020 | |
| Harmony Biosciences LLC | $13.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Bartky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.